Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Relapsed or refractory CD30-positive peripheral T cell lymphoma or Pediatric Hodgkin Lymphoma
Not Applicable
Completed
- Conditions
- Peripheral T cell lymphoma and Pediatric Hodgkin lymphoma
- Registration Number
- JPRN-jRCT1080224999
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 95
Inclusion Criteria
1. Participants with relapsed or refractory lymphoma.
2. CD30-positive participants.
3. Participants who receive study drug after obtaining approval of CD30-positive PTCL indication of study drug.
Exclusion Criteria
1. Participants with a history of severe hypersensitivity to Brentuximab Vedotin.
2. Participants taking bleomycin hydrochloride treatment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method